INTS Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Intensity Therapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerINTS

Market Cap12.0M

Cash RunwayRunway 6-12 months

Next Catalyst2027-01

Public Research Snapshot

Intensity Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for INT230 in specific soft tissue sarcoma subtypes (Phase 3).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Increased Survival	n/a	n/a	Phase 1/2	Public pipeline row
INT230	specific soft tissue sarcoma subtypes	n/a	Phase 3	Public pipeline row
Ultrasonic Diathermy Device	Knee Osteoarthritis	n/a	Na	Public pipeline row
Tinlarebant	Stargardt Disease 1	n/a	Phase 3	Public pipeline row
Pirtobrutinib	Lymphoma, Mantle-Cell	n/a	Phase 3	Public pipeline row
Tocilizumab	Rheumatoid Arthritis	n/a	Phase 3	Public pipeline row
Guselkumab	Arthritis, Psoriatic	n/a	Phase 3	Public pipeline row

Catalyst Preview

Catalyst	Timing	Asset	Confidence
Clinical Trial Completion	2027-01	Pirtobrutinib	Low
Corporate Update	Timing not specified	n/a	Low
Enrollment Update	second quarter of 2026	n/a	Low

Cash Runway Preview

Estimated cash runway: Runway 6-12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT01007435	Phase 3	COMPLETED	1162	2012-05-31
NCT01993693	Na	TERMINATED	15	2014-07
NCT04936308	Phase 3	ACTIVE_NOT_RECRUITING	453	2024-10-28
NCT05244304	Phase 3	COMPLETED	104	2025-08-04
NCT04662255	Phase 3	ACTIVE_NOT_RECRUITING	500	2027-01

Scientific Context

catalyst_type | Corporate Update
catalyst_type | Enrollment Update
catalyst_window | second quarter of 2026
literature_publication | Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.
asset_name | Guselkumab

Want the full INTS research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.